Related Experiment Video
Updated: Mar 31, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.4K
Non-coding RNA biomarkers in resistant hypertension: a scoping review.
Robert Błaszczyk1, Maciej Biskupski2, Łukasz Wiśniowski1
1Department of Cardiology, Medical University of Lublin, Lublin, Poland.
Frontiers in Molecular Biosciences
|March 30, 2026
Summary
Evidence on circulating non-coding RNAs (ncRNAs) as biomarkers for resistant hypertension (RH) is limited. While some microRNAs (miRNAs) and circular RNAs (circRNAs) show potential associations, more robust studies are needed for clinical use.
Area of Science:
- Biomarkers
- Genomics
- Hypertension Research
Background:
- Resistant hypertension (RH) presents a significant clinical challenge.
- Circulating non-coding RNAs (ncRNAs) are emerging as potential biomarkers.
- Evidence linking ncRNAs to RH phenotypes and treatment response requires synthesis.
Purpose of the Study:
- To map and synthesize human evidence on circulating ncRNAs as biomarkers in RH.
- To explore associations with RH phenotypes, target-organ damage, and treatment response.
Main Methods:
- A comprehensive scoping review was performed using PubMed, Web of Science, and Google Scholar.
- Eligible studies included original human research on RH, focusing on peripheral blood matrices.
- Data were qualitatively synthesized due to heterogeneity in methodology and analytic rigor.
Main Results:
- Eight studies (2013-2024) involving 338 RH participants were included, focusing on microRNAs (miRNAs) and circular RNAs (circRNAs).
- Reported associations include elevated serum miR-21 in RH, specific miRNA panels for treatment response prediction, and changes post-renal sympathetic denervation (RDN).
- Methodological variability and lack of external validation were noted across studies.
Conclusions:
- Current evidence on circulating ncRNA biomarkers in RH is sparse and fragmented.
- Individual studies suggest potential associations, but data are insufficient for clinical implementation.
- Larger, well-designed multicenter studies with standardized assays and robust validation are necessary.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
746
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
746
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:18Hypertension and Regulation of Blood Pressure
4.8K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.8K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.8K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
715
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
715